Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from real-life setting

The authors are commenting on the study entitled: “Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from rel-life setting” published by Lukic et al. in European Journal Ophthalmology 2020 (Doi: 10.1177/1120672120938565. Published on June 25, 2020), which assessed 4-year structural and functional outcomes in intravitreal aflibercept treatment for 89 patients (94 eyes) with neovascular age-related macular degeneration in a real-world setting. The authors concluded that there was a significant improvement in visual acuity and in anatomical outcomes in aflibercept-treated eyes at 4 years after commencing treatment. However, the validation, extrapolation, and generalizabilty of these findings can only be made by statistical analyses including all the missing baseline potential risk factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the key metrics assessing the efficacy of intravitreal aflibercept for neovascular age-related macular degeneration.